Fresenius Medical Care Confirms Positive Outlook for 2009
Shareholders Approve Twelfth Consecutive Annual Dividend Increase
Lipps also expects continued sustainable growth driven by an annual 5% to 6% increase of patients requiring dialysis treatment. Furthermore, Fresenius Medical Care will pursue strategic opportunities to consolidate its leading market positions. Key drivers of these opportunities include: increasing market share through a superior product portfolio, the introduction of a bundled payment system in the U.S. and Portugal, expanding the clinic network, launching the renal pharma initiative and rolling out additional dialysis services.
Lipps also pointed out that, despite the global financial crisis, Fresenius Medical Care enjoyed a significant increase in the number of employees. The addition of 3,260 people, an increase of 5.3% to a total of 65,000 employees worldwide, was attributed primarily to strong organic growth of the dialysis care business in every region. Selected acquisitions in Europe and Asia also contributed to this growth. The number of employees is expected to rise again in 2009.
During the Annual General Meeting, the shareholders approved the twelfth consecutive dividend increase with a large majority of 99.98%. The dividend will increase to €0.58 from €0.54 per ordinary share and to €0.60 from €0.56 per preference share.
In addition, shareholders affirmed the actions taken and decisions made by the Supervisory Board and the Management Board with a majority of more than 99%.
At the Annual General Meeting, 74.62% of the ordinary share capital and 3.65% of the preference share capital were represented. Only ordinary shareholders were entitled to vote.
(1) Net income attributable to FMC AG & Co. KGaA
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius AG (SE)
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis due to chronic kidney failure, a condition that affects more than 1,770,000 individuals worldwide. Through its network of 2,448 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa, Fresenius Medical Care provides dialysis treatment to 187,476 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers, and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).
For more information about Fresenius Medical Care, visit the company's website at www.fmc-ag.com.